The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey.

"CONFLICT OF INTEREST DISCLOSURES This study was sponsored by Glaxo SmithKline Asia Pacific (Singapore). Dr. Aggarwal has acted as a consultant for Glaxo SmithKline, AstraZeneca, Dabur, and Roche, and has received honoraria from GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca, and Merck. Drs. Yip and Sunpaweravong have acted as consultants for GlaxoSmithKline. Drs. Yeoh and Moon are employees of GlaxoSmithKline Asia Pacific. The authors acknowledge the independent medical writing assistance provided by ProScribe Medical Communications (http://www.proscribe.com.au [accessed July 23, 2010]), funded from an unrestricted financial grant from GlaxoSmithKline Asia Pacific. ProScribe's services complied with international guidelines for Good Publication Practice."

"This study was sponsored by Glaxo SmithKline Asia Pacific (Singapore). Dr. Aggarwal has acted as a consultant for Glaxo SmithKline, AstraZeneca, Dabur, and Roche, and has received honoraria from GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca, and Merck. Drs. Yip and Sunpaweravong have acted as consultants for GlaxoSmithKline. Drs. Yeoh and Moon are employees of GlaxoSmithKline Asia Pacific. The authors acknowledge the independent medical writing assistance provided by ProScribe Medical Communications (http://www.proscribe.com.au [accessed July 23, 2010]), funded from an unrestricted financial grant from GlaxoSmithKline Asia Pacific. ProScribe's services complied with international guidelines for Good Publication Practice."